Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. director Oren Ilan received an award of 775 Common Shares on July 17, 2026 at $0.0000 per share under the company’s Non-Employee Director Compensation Plan, fully vested as of the grant date.
After this grant, Ilan directly holds 121,004 Common Shares; the transaction is reported as a grant/award acquisition and was not made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. director and CEO Matthew Gline reported a routine tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the company withheld 76,171 common shares, valued at $35.39 per share, to cover applicable tax obligations through a net settlement. Following this transaction, Gline directly holds 16,659,945 common shares, indicating he retains a substantial equity position in the company and that the reported disposition reflects tax withholding rather than an open-market sale.
Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares. She exercised stock options to acquire 10,000 common shares at $8.80 per share and on the same date sold 10,000 common shares at an average price of $34.90 per share.
Following these transactions, Fitzgerald directly holds 42,963 common shares of Roivant Sciences. The derivative entry shows 38,578 stock options remaining after the exercise, indicating she continues to have a meaningful option position as well as a direct equity stake.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 40,310 common shares withheld on June 30, 2026 to cover tax obligations. The shares were "net settled" from previously granted RSUs when they vested, rather than sold in the open market.
After this tax-withholding disposition, Torti directly holds 13,536,202 common shares, indicating this was a routine compensation-related event rather than a change in his overall investment stance.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme had 46,878 Common Shares withheld on June 30, 2026 at $35.39 per share. This was a tax-withholding disposition tied to the vesting of previously granted RSUs, not an open-market trade. After this net settlement, he directly holds 18,630,739 Common Shares.
Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026. She exercised options to acquire 17,750 Common Shares at an exercise price of $4.46 per share, increasing her direct common share holdings before subsequent sales.
That same day, she executed open-market sales totaling 17,750 Common Shares in two transactions: 2,748 shares at a weighted average price of $34.71 and 15,002 shares at a weighted average price of $34.32. The footnotes state these were filled across multiple trades within price ranges from $33.65 to $34.80. After the transactions, Epperly directly held 16,474 Common Shares and 169,166 stock options to purchase additional shares, with the option grant exercised here fully vested and expiring on July 19, 2032.
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share. The filing shows 200,000 shares sold from his direct holdings, leaving 1,748,403 shares held directly, and additional sales by QVT Financial Investment Cayman Ltd., which held 13,689,166 shares afterward. Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of those shares except for his pecuniary interest.
Roivant Sciences Ltd. reported insider-related share sales linked to an investment entity associated with director Daniel Allen Gold. QVT Financial Investment Cayman Ltd. completed open-market sales of a total of 1,438,163 common shares of Roivant Sciences over three days, at prices between $33.92 and $35.28 per share. After the most recent transaction, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares indirectly. Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Roivant Sciences Ltd. disclosed that investment firm QVT Financial LP, through QVT Financial Investment Cayman Ltd., executed open-market sales of a total of 1,438,163 common shares over three days at prices around $33.92–$35.28 per share. Following these transactions, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares, while footnotes state that QVT Financial LP may be deemed to beneficially own 23,723,074 Roivant common shares across related entities, although it disclaims beneficial ownership beyond any pecuniary interest.